LILRA6

Across TCGA pan-cancer cohorts, LILRA6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LILRA6 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LILRA6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LILRA6 expression acts as an unfavorable survival marker.

LUSC, COAD, and LUAD are the cancer types where LILRA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.064	0.791	<.001	20	view →
COAD	OS	Median	II,III,IV	0.001	0.860	<.001	9	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
LGG	OS	Median	All	0.294	0.799	.005	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LILRA6–LUSC (DFS)

Open the LUSC breakdown →